Cargando…

The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis

BACKGROUND: GeneXpert MTB/RIF testing is a rapid molecular diagnostic test that is performed with an automated cartilage-based machine that makes treatment initiation prompt. This study aimed at evaluating the impact of GeneXpert in the reduction of treatment delay among multidrug-resistant tubercul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamirat, Koku Sisay, Kebede, Fentahun Bikale, Baraki, Adhanom Gebreegziabher, Akalu, Temesgen Yihunie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803608/
https://www.ncbi.nlm.nih.gov/pubmed/35115796
http://dx.doi.org/10.2147/IDR.S345619
_version_ 1784642903484661760
author Tamirat, Koku Sisay
Kebede, Fentahun Bikale
Baraki, Adhanom Gebreegziabher
Akalu, Temesgen Yihunie
author_facet Tamirat, Koku Sisay
Kebede, Fentahun Bikale
Baraki, Adhanom Gebreegziabher
Akalu, Temesgen Yihunie
author_sort Tamirat, Koku Sisay
collection PubMed
description BACKGROUND: GeneXpert MTB/RIF testing is a rapid molecular diagnostic test that is performed with an automated cartilage-based machine that makes treatment initiation prompt. This study aimed at evaluating the impact of GeneXpert in the reduction of treatment delay among multidrug-resistant tuberculosis (MDR-TB) patients in Amhara regional state of Ethiopia. METHODS: A facility-based retrospective follow-up study was conducted from January to February 2019, and a total of 465 MDR-TB patients were included in the study. Socio-demographic, clinical, and treatment-related characteristics were collected from patient’s chart retrospectively using data abstraction sheets. Binary logistic regression model was fitted to identify factors associated with treatment delay; adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to assess the strength of association. A propensity score-matched (PSM) analysis was used to assess the impact of the GeneXpert MTB/RIF test on treatment delay through calculation of average treatment effect (ATE). RESULTS: The majority, 92.4%, of patients had the pulmonary form of TB, and 46.7% of patients were diagnosed by GeneXpert MTB/RIF. The presence of cavitation (AOR = 0.62, 95% CI: 0.39 0.96), extrapulmonary form of TB (AOR = 0.34, 95% CI: 0.14 0.81), and GeneXpert (AOR = 0.15, 95% CI: 0.10 0.24) were factors associated with treatment delay. The average treatment effect (ATE) of PSM analysis showed that GeneXpert MTB/RIF has significantly reduced treatment delay by 41% compared to matched control groups. CONCLUSION: This study revealed that GeneXpert test has a strong association with the reduced treatment delays among MDR-TB patients. This underscores that rapid molecular tests could help improve the health system and lead to prompt initiation of MDR-TB treatment. Therefore, expansion and decentralization of GeneXpert tests to peripheral health facilities are highly recommended. In turn, the case detection and control of the disease will be hastened.
format Online
Article
Text
id pubmed-8803608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88036082022-02-02 The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis Tamirat, Koku Sisay Kebede, Fentahun Bikale Baraki, Adhanom Gebreegziabher Akalu, Temesgen Yihunie Infect Drug Resist Original Research BACKGROUND: GeneXpert MTB/RIF testing is a rapid molecular diagnostic test that is performed with an automated cartilage-based machine that makes treatment initiation prompt. This study aimed at evaluating the impact of GeneXpert in the reduction of treatment delay among multidrug-resistant tuberculosis (MDR-TB) patients in Amhara regional state of Ethiopia. METHODS: A facility-based retrospective follow-up study was conducted from January to February 2019, and a total of 465 MDR-TB patients were included in the study. Socio-demographic, clinical, and treatment-related characteristics were collected from patient’s chart retrospectively using data abstraction sheets. Binary logistic regression model was fitted to identify factors associated with treatment delay; adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to assess the strength of association. A propensity score-matched (PSM) analysis was used to assess the impact of the GeneXpert MTB/RIF test on treatment delay through calculation of average treatment effect (ATE). RESULTS: The majority, 92.4%, of patients had the pulmonary form of TB, and 46.7% of patients were diagnosed by GeneXpert MTB/RIF. The presence of cavitation (AOR = 0.62, 95% CI: 0.39 0.96), extrapulmonary form of TB (AOR = 0.34, 95% CI: 0.14 0.81), and GeneXpert (AOR = 0.15, 95% CI: 0.10 0.24) were factors associated with treatment delay. The average treatment effect (ATE) of PSM analysis showed that GeneXpert MTB/RIF has significantly reduced treatment delay by 41% compared to matched control groups. CONCLUSION: This study revealed that GeneXpert test has a strong association with the reduced treatment delays among MDR-TB patients. This underscores that rapid molecular tests could help improve the health system and lead to prompt initiation of MDR-TB treatment. Therefore, expansion and decentralization of GeneXpert tests to peripheral health facilities are highly recommended. In turn, the case detection and control of the disease will be hastened. Dove 2022-01-27 /pmc/articles/PMC8803608/ /pubmed/35115796 http://dx.doi.org/10.2147/IDR.S345619 Text en © 2022 Tamirat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tamirat, Koku Sisay
Kebede, Fentahun Bikale
Baraki, Adhanom Gebreegziabher
Akalu, Temesgen Yihunie
The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title_full The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title_fullStr The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title_full_unstemmed The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title_short The Role of GeneXpert MTB/RIF in Reducing Treatment Delay Among Multidrug Resistance Tuberculosis Patients: A Propensity Score Matched Analysis
title_sort role of genexpert mtb/rif in reducing treatment delay among multidrug resistance tuberculosis patients: a propensity score matched analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803608/
https://www.ncbi.nlm.nih.gov/pubmed/35115796
http://dx.doi.org/10.2147/IDR.S345619
work_keys_str_mv AT tamiratkokusisay theroleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT kebedefentahunbikale theroleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT barakiadhanomgebreegziabher theroleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT akalutemesgenyihunie theroleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT tamiratkokusisay roleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT kebedefentahunbikale roleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT barakiadhanomgebreegziabher roleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis
AT akalutemesgenyihunie roleofgenexpertmtbrifinreducingtreatmentdelayamongmultidrugresistancetuberculosispatientsapropensityscorematchedanalysis